External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Metabolism ICO 2026
Roche and Genentech at

ICO 2026

July 15 - July 17
Mexico City, Mexico
icocongress.com
We will be contributing to topics related to
Metabolism
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
06:00 AM
Duration 60mins Mexico City, Mexico
Enicepatide, a cAMP Dual Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Reduction in People With Overweight/Obesity: a 48-Week Phase 2 Study
Jeffrey Willis, Ildiko Lingvay, Alexandra Steinberg, Carel Le-Roux, Ania Jastreboff, Stephan Sharp, Sureka Bollepalli, Kenneth Kim, Dan Lender, Harold Bays, Giuseppe Palermo, Esther Shearer-Kang, Manu Chakravarthy
Metabolism | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.